Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (312)	8/10/2003 8:28:13 AM
From: Madharry	Read Replies (1) of 824

Based on your numerical analysis it seems like a safe assumption that ALXN was close to achieving the primary endpoint for CABG. If the target was 30% and they only achieved 25%, is that not sufficiently meaningful for approval? especially if there are no safety issues. I think that one of the considerations will be financial- what are the costs of treating heart attacks versus preventing a certain percentage of them . Although I am not happy about this non release of information, this would also preclude andy insider trading in the stock until the results are officialy released-so this decision affects managment as well. I consider this type of decision far less harmful than the convertible bond issuances with the price to be determined later.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next